Answers are grounded in this paper and cite their sources.
Cystic kidney diseases are an important cause of pediatric morbidity and mortality. Most genetic cystic kidney diseases are "ciliopathies", a group of disorders that share a common feature of abnormal structure or function of the primary cilia. Ciliopathies represent a broad range of clinically and genetically heterogenous disorders, which affect multiple organ systems. Autosomal dominant polycystic kidney disease (ADPKD) and autosomal recessive polycystic kidney disease (ARPKD) are the 2 most common etiologies, affecting 1:1000-2500 and 1:20,000-40,000 individuals, respectively. Although historically referred to as "adult" (ADPKD) and "infantile" (ARPKD) polycystic kidney disease, it is now understood that age at presentation is variable. Approximately 3% of ADPKD patients present with very early onset, severe features that mimic ("phenocopy") typical ARPKD. Similarly, a minority of ARPKD cases present as late as young adulthood. Due to their heterogeneity, ADPKD, ARPKD, and other phenocopies, such as hepatocyte nuclear factor-1 beta-associated kidney disease, can be difficult to distinguish clinically, making molecular genetic testing a valuable diagnostic resource. The purpose of this review is to provide a comprehensive overview of the clinical and genetic spectrum and molecular diagnosis of cystic kidney diseases in children, with a specific focus on ADPKD and ARPKD.
No takes yet. Share an insight, caveat, or question.
Borden et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: